Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann; K. Fizazi; N. Shore; T. L. Tammela; A. Ulys; E. Vjaters; S. Polyakov; M. Jievaltas; M. Luz; B. Alekseev; I. Kuss; M. -A. Le Berre; O. Petrenciuc; A. Snapir; T. Sarapohja; M. R. Smith

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann
, K. Fizazi
, N. Shore
, T. L. Tammela
, A. Ulys
, E. Vjaters
, S. Polyakov
, M. Jievaltas
, M. Luz
, B. Alekseev
, I. Kuss
, M. -A. Le Berre
, O. Petrenciuc
, A. Snapir
, T. Sarapohja
, M. R. Smith

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	149
Pages (from-to)	225-225
Number of pages	1
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
Publication status	Published - Oct 2020
Externally published	Yes
Event	Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology - virtual /Congress Center Basel, Basel, Switzerland Duration: 9 Oct 2020 → 11 Oct 2020 https://www.messe-basel.com/en/news/2020/dgho-in-basel-switzerlands-first-large-scale-digital-congress/ https://boardroom.global/physicians-can-still-get-together-in-basel/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this

Boegemann, M., Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M. .-A., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Oncology Research and Treatment, 43(SUPPL 4), 225-225. Article 149.

@article{398242a565d9439bbce3bbffdda08409,

title = "Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)",

author = "M. Boegemann and K. Fizazi and N. Shore and Tammela, \{T. L.\} and A. Ulys and E. Vjaters and S. Polyakov and M. Jievaltas and M. Luz and B. Alekseev and I. Kuss and \{Le Berre\}, \{M. -A.\} and O. Petrenciuc and A. Snapir and T. Sarapohja and Smith, \{M. R.\}",

year = "2020",

month = oct,

language = "English",

volume = "43",

pages = "225--225",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "SUPPL 4",

note = "Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology ; Conference date: 09-10-2020 Through 11-10-2020",

url = "https://www.messe-basel.com/en/news/2020/dgho-in-basel-switzerlands-first-large-scale-digital-congress/, https://boardroom.global/physicians-can-still-get-together-in-basel/",

}

Boegemann, M, Fizazi, K, Shore, N, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Kuss, I, Le Berre, M-A, Petrenciuc, O, Snapir, A, Sarapohja, T & Smith, MR 2020, 'Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)', Oncology Research and Treatment, vol. 43, no. SUPPL 4, 149, pp. 225-225.

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). / Boegemann, M.; Fizazi, K.; Shore, N. et al.
In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 149, 10.2020, p. 225-225.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

AU - Boegemann, M.

AU - Fizazi, K.

AU - Shore, N.

AU - Tammela, T. L.

AU - Ulys, A.

AU - Vjaters, E.

AU - Polyakov, S.

AU - Jievaltas, M.

AU - Luz, M.

AU - Alekseev, B.

AU - Kuss, I.

AU - Le Berre, M. -A.

AU - Petrenciuc, O.

AU - Snapir, A.

AU - Sarapohja, T.

AU - Smith, M. R.

PY - 2020/10

Y1 - 2020/10

UR - https://www-webofscience-com.db.rsu.lv/wos/woscc/full-record/WOS:000575955000507

M3 - Meeting Abstract

SN - 2296-5270

VL - 43

SP - 225

EP - 225

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 4

M1 - 149

T2 - Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology

Y2 - 9 October 2020 through 11 October 2020

ER -

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

UN SDGs

Field of Science*

Publication Type*

Other files and links

Cite this